Evolving role of pharmaceutical physicians in medical evidence and education

Setia, Sajita; Ryan, Nicola; Nair, Prasad S; Ching, Elma; Subramaniam, Kannan

doi:10.2147/amep.s175683

Cited by 23 publications

(19 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sustainability of these initiatives is the biggest challenge; there is a good opportunity for the private sector to provide funding. 94,95 With ready access to the internet on mobile devices, patients are no longer passive recipients of care. Patients are increasingly assuming the role of health consumers with autonomy, demanding health information and the ability to choose.…”

Section: Education For All Sectors and The Inclusion Of Patientsmentioning

confidence: 99%

Systemic Solutions for Addressing Non-Communicable Diseases in Low- and Middle-Income Countries

Ganju¹,

Goulart²,

Majumdar³

et al. 2020

JMDH

Self Cite

View full text Add to dashboard Cite

Non-communicable diseases (NCDs) have been on the rise in low-and middleincome countries (LMICs) over the last few decades and represent a significant healthcare concern. Over 85% of "premature" deaths worldwide due to NCDs occur in the LMICs. NCDs are an economic burden on these countries, increasing their healthcare expenditure. However, targeting NCDs in LMICs is challenging due to evolving health systems and an emphasis on acute illness. The major issues include limitations with universal health coverage, regulations, funding, distribution and availability of the healthcare workforce, and availability of health data. Experts from across the health sector in LMICs formed a Think Tank to understand and examine the issues, and to offer potential opportunities that may address the rising burden of NCDs in these countries. This review presents the evidence and posits pragmatic solutions to combat NCDs.

show abstract

Section: Education For All Sectors and The Inclusion Of Patientsmentioning

confidence: 99%

Systemic Solutions for Addressing Non-Communicable Diseases in Low- and Middle-Income Countries

Ganju¹,

Goulart²,

Majumdar³

et al. 2020

JMDH

Self Cite

View full text Add to dashboard Cite

show abstract

“…Even in developed nations, CMEs cost many billions per year and only less than half of this revenue is contributed by the learners themselves 35. CME is largely supported by commercial sponsors, such as manufacturers of pharmaceuticals and medical devices, who contribute through unrestricted educational grants and other funding approaches to cover the costs of CME activities 35,36. In certain European countries and Canada, this accounts for about 75% of all CME provision 37,38.…”

Section: Moocs – Limitations and Solutionsmentioning

confidence: 99%

Massive open online courses (MOOCs) for continuing medical education – why and how?

Setia¹,

Tay²,

Chia³

et al. 2019

AMEP

Self Cite

View full text Add to dashboard Cite

Continuing medical education (CME) is meant to not only improve clinicians' knowledge and skills but also lead to better patient care processes and outcomes. The delivery of CME should be able to encourage the health providers to accept new evidencebased practices, and discard or discontinue less effective care. However, continuing use of expensive yet least effective and inappropriate tools and techniques predominates for CME delivery. Hence, the evidence shows a disconnect between evidence-based recommendations and real-world practiceborne out by less than optimal patient outcomes or treatment targets not being met especially in low-to middle-income countries. There is an ethical and professional obligation on CME-providers and decision-makers to safeguard that CME interventions are appraised not only for their quality and effectiveness but also for costeffectiveness. The process of learning needs to be engaging, convenient, user-friendly and of minimal cost, especially where it is most needed. Today's technology permits these characteristics to be integrated, along with further enhancement of the engagement process. We review the literature on the mechanics of CME learning that utilizes today's technology tools and propose a framework for more engaging, efficient and cost-effective approach that implements massive open online courses for CME, adapted for the twenty-first century.

show abstract

“…As alluded to earlier, pharmaceutical companies can also interact with prescribers through non-promotional representatives, typically members of the company's medical department; these 'non-promotional personal engagement activities' (see Table 1) are becoming increasingly popular with both healthcare practitioners (HCPs) and pharmaceutical companies [12]. They consist of engagements focused around creating the discussed peer-to-peer relationships between prescribers and pharmaceutical physicians.…”

Section: Key Pointsmentioning

confidence: 99%

Influence of Pharmaceutical Company Engagement Activities on the Decision to Prescribe: A Pilot Survey of UK Rare Disease Medicine Prescribers

Jandhyala

2020

Pharm Med

View full text Add to dashboard Cite

Introduction Traditionally, the pharmaceutical industry has used 'promotional personal engagement' activities, which involve interactions between sales forces and prescribers, in order to generate 'sales'-or prescriptions-of their new medicinal product(s). There appears to be now a favouring of 'non-personal engagement' (external information sources or activities existing outside the direct control of the company) and 'non-promotional personal engagement' activities (focused around creating peer-to-peer relationships between prescribers and pharmaceutical physicians). Objectives The purpose of this study was to examine the influence of non-personal engagement and non-promotional personal engagement activities on the prescribing habits of British healthcare professionals, using the traditional promotional personal engagement activities as a comparator. Methods A questionnaire was distributed to 122 prescribers (physicians, nurses and pharmacists) working with two selected products for pulmonary arterial hypertension. The participants were asked to rate the influence that the listed activities had on their decision to prescribe each of the two products using a scale of 0-10, where 0 = 'no influence' and 10 = 'most important influence'. Results Of the 122 targeted healthcare professionals who received the questionnaire, 34 (27.9%) responded within the 2-week time limit (24 physicians, 5 nurse prescribers and 5 pharmacists). The findings of the survey had a confidence level of 90% and a margin of error of 12%, given that 34 of 122 people responded. All proposed activities were scored by the respondents as having some influence on their prescribing. Personal engagement activities are effective for influencing prescribing, but non-promotional personal engagement activities may be more influential than promotional personal engagement activities. Furthermore, non-personal engagement activities may be more effective in influencing prescriptions of a product than either non-promotional or promotional personal engagement activities. Conclusions All personal engagement activities affect HCP prescribing behaviours; however, they appear to be more influential when performed on a non-promotional basis by representatives of the company's medical department.

show abstract

Evolving role of pharmaceutical physicians in medical evidence and education

Cited by 23 publications

References 61 publications

<p>Systemic Solutions for Addressing Non-Communicable Diseases in Low- and Middle-Income Countries</p>

<p>Systemic Solutions for Addressing Non-Communicable Diseases in Low- and Middle-Income Countries</p>

<p>Massive open online courses (MOOCs) for continuing medical education – why and how?</p>

Influence of Pharmaceutical Company Engagement Activities on the Decision to Prescribe: A Pilot Survey of UK Rare Disease Medicine Prescribers

Contact Info

Product

Resources

About